Organ-based drug delivery

References

• Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. Tissue Barriers. 2014;2: e29528.
   PubMedGoogle Scholar
• Calcagno AM, TJ. Siahaan Physiological, biochemical, and chemical barriers to oral drug delivery. In: Wang B, Siahaan T, Soltero R, eds. Drug delivery. New Jersey: John Wiley & Sons, Inc.; 2005. p. 15–27.
   Google Scholar
• Perrie Y, Badhan RK, Kirby DJ, et al. The impact of ageing on the barriers to drug delivery. J Control Release. 2012; 161:389–398.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64:640–665.
   PubMed Web of Science ®Google Scholar
• Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem Soc. 2016;138:704–717.
   PubMed Web of Science ®Google Scholar
• Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov. 2005;4:381–385.
   PubMed Web of Science ®Google Scholar
• Duvillard C, Polycarpe E, Romanet P, et al. Intratumoral chemotherapy: experimental data and applications to head and neck tumors. Ann Otolaryngol Chir Cervicofac. 2007;124:53–60.
   PubMedGoogle Scholar
• Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy. Nat Rev Rheumatol. 2014;10:11–22.
   PubMed Web of Science ®Google Scholar
• Mody VV, Cox A, Shah S, et al. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl Nanosci. 2014;4:385–392.
   Web of Science ®Google Scholar
• Giang I, Boland EL, Poon GM. Prodrug applications for targeted cancer therapy. Aaps J. 2014;16:899–913.
   PubMed Web of Science ®Google Scholar
• Yu X, Trase I, Ren M, et al. Design of nanoparticle-based carriers for targeted drug delivery. J Nanomater. 2016; 2016:1087250.
   PubMedGoogle Scholar
• Hirsjarvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol. 2011;8:188–196.
   PubMedGoogle Scholar
• Dufort S, Sancey L, Coll JL. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev. 2012;64:179–189.
   PubMed Web of Science ®Google Scholar
• Santos-Magalhaes NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev. 2010;62:560–575.
   PubMed Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, et al. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17:31–48.
   Web of Science ®Google Scholar
• Crielaard BJ, Lammers T, Schiffelers RM, et al. Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release. 2012;161:225–234.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv. 2013;4: 421–423.
   PubMedGoogle Scholar
• Lamprecht A. Nanomedicines in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2015;12: 195–204.
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991–1003.
   PubMed Web of Science ®Google Scholar
• Lopes JR, Santos G, Barata P, et al. Physical and chemical stimuli-responsive drug delivery systems: targeted delivery and main routes of administration. Curr Pharm Des. 2013;19:7169–7184.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626.
   PubMed Web of Science ®Google Scholar
• Tang Y, Soroush F, Tong Z, et al. Targeted multidrug delivery system to overcome chemoresistance in breast cancer. Int J Nanomed. 2017;12:671–681.
   PubMed Web of Science ®Google Scholar
• Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001;74: 95–113.
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65:11631–11638.
   PubMed Web of Science ®Google Scholar
• Zhou S, Wu D, Yin X, et al. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells. J Exp Clin Cancer Res. 2017;36:24.
   PubMed Web of Science ®Google Scholar
• Jin SE, Jin HE, Hong SS. Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. BioMed Res Int. 2014;2014:23.
   Web of Science ®Google Scholar
• Griffiths GL, Govindan SV, Sharkey RM, et al. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003;44:77–84.
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2008;126:50–58.
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Liu B, Munker R, et al. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res. 1998;4:1971–1976.
   PubMed Web of Science ®Google Scholar
• FitzGerald DJ, Waldmann TA, Willingham MC, et al. Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. J Clin Invest. 1984;74:966–971.
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30–38.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Bagshawe KD, Burke PJ, et al. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer. 1994; 73(Suppl. 3):1114–1120.
   Web of Science ®Google Scholar
• Syrigos KN, Rowlinson-Busza G, Epenetos AA. In vitro cytotoxicity following specific activation of amygdalin by β-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer. 1998;78:712–719.
   PubMed Web of Science ®Google Scholar
• Nukolova NV, Yang Z, Kim JO, et al. Polyelectrolyte nanogels decorated with monoclonal antibody for targeted drug delivery. React Funct Polym. 2011;71:315–323.
   PubMed Web of Science ®Google Scholar
• Deckert PM, Bornmann WG, Ritter G, et al. Specific tumour localisation of a huA33 antibody-carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. Int J Oncol. 2004;24:1289–1295.
   PubMed Web of Science ®Google Scholar
• Liu J, Kopeckova P, Buhler P, et al. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm. 2009; 6:959–970.
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961–2973.
   PubMed Web of Science ®Google Scholar
• Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008;1786:126–138.
   PubMed Web of Science ®Google Scholar
• Azhdarinia A, Daquinag AC, Tseng C, et al. A peptide probe for targeted brown adipose tissue imaging. Nat Commun. 2013;4:2472.
   PubMed Web of Science ®Google Scholar
• Lee NK, Kim HS, Kim KH, et al. Identification of a novel peptide ligand targeting visceral adipose tissue via transdermal route by in vivo phage display. J Drug Target. 2011;19:805–813.
   PubMed Web of Science ®Google Scholar
• Geng Q, Sun X, Gong T, et al. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery. Bioconjugate Chem. 2012;23:1200–1210.
   PubMed Web of Science ®Google Scholar
• Xin H, Sha X, Jiang X, et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles. Biomaterials. 2012;33:1673–1681.
   PubMed Web of Science ®Google Scholar
• Laakkonen P, Porkka K, Hoffman JA, et al. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002;8:751–755.
   PubMed Web of Science ®Google Scholar
• Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett. 2001;171:153–164.
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123–132.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006;103:6315–6320.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu H, Sefah K, et al. Selection of aptamers specific for adipose tissue. PLoS One. 2012;7:e37789.
   PubMed Web of Science ®Google Scholar
• Zhao N, You J, Zeng Z, et al. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small. 2013;9:3477–3484.
   PubMed Web of Science ®Google Scholar
• Li X, Yu Y, Ji Q, et al. Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. Nanomedicine. 2015; 11:175–184.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. Transferrin receptors and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012; 1820:291–317.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5:309–319.
   PubMed Web of Science ®Google Scholar
• Fallon RJ, Schwartz AL. Receptor-mediated delivery of drugs to hepatocytes. Adv Drug Deliv Rev. 1989;4:49–63.
   Google Scholar
• Wu F, Wuensch SA, Azadniv M, et al. Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Mol Pharm. 2009;6:1506–1517.
   PubMed Web of Science ®Google Scholar
• Kuai R, Li D, Chen YE, et al. High-density lipoproteins: nature’s multifunctional nanoparticles. ACS Nano. 2016; 10:3015–3041.
   PubMed Web of Science ®Google Scholar
• Neumann E, Frei E, Funk D, et al. Native albumin for targeted drug delivery. Expert Opin Drug Deliv. 2010;7: 915–925.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8:1004–1013.
   PubMed Web of Science ®Google Scholar
• Dharap SS, Wang Y, Chandna P, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA. 2005;102:12962–12967.
   PubMed Web of Science ®Google Scholar
• Shimada T, Ueda M, Jinno H, et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 2009;29:1009–1014.
   PubMed Web of Science ®Google Scholar
• Witzigmann D, Detampel P, Porta F, et al. Isolation of multiantennary N-glycans from glycoproteins for hepatocyte specific targeting via the asialoglycoprotein receptor. RSC Adv. 2016;6:97636–97640.
   Web of Science ®Google Scholar
• Yoshida M, Takimoto R, Murase K, et al. Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. PLoS One. 2012; 7:e39545.
   PubMed Web of Science ®Google Scholar
• Bies C, Lehr CM, Woodley JF. Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev. 2004; 56:425–435.
   PubMed Web of Science ®Google Scholar
• Bartneck M, Warzecha KT, Tacke F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr. 2014;3:364–376.
   PubMedGoogle Scholar
• Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci. 2002;7:717–725.
   PubMed Web of Science ®Google Scholar
• Shen Z, Wei W, Tanaka H, et al. A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. Pharmacol Res. 2011;64:410–419.
   PubMed Web of Science ®Google Scholar
• Schellmann N, Deckert PM, Bachran D, et al. Targeted enzyme prodrug therapies. Mini Rev Med Chem. 2010; 10:887–904.
   PubMed Web of Science ®Google Scholar
• Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001;7:3314–3324.
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Singh A, Mohanty C, et al. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials. 2010;31:3694–3706.
   PubMed Web of Science ®Google Scholar
• Nomikou N, Li YS, McHale AP. Ultrasound-enhanced drug dispersion through solid tumours and its possible role in aiding ultrasound-targeted cancer chemotherapy. Cancer Lett. 2010;288:94–98.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Akimoto J, Okano T. Polymeric micelles with stimuli-triggering systems for advanced cancer drug targeting. J Drug Target. 2014;22:584–599.
   PubMed Web of Science ®Google Scholar
• Kumar CS, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev. 2011;63:789–808.
   PubMed Web of Science ®Google Scholar
• Gasselhuber A, Dreher MR, Partanen A, et al. Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivo validation. Int J Hyperthermia. 2012;28: 337–348.
   PubMed Web of Science ®Google Scholar
• Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci USA. 2010;107:15205–15210.
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Witt C, Wagner U, et al. Fundamentals of pulmonary drug delivery. Respir Med. 2003;97:382–387.
   PubMed Web of Science ®Google Scholar
• Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv. 2010;23:207–217.
   PubMed Web of Science ®Google Scholar
• Van der Schans CP. Bronchial mucus transport. Respir Care. 2007;52:1150–1156.
   PubMed Web of Science ®Google Scholar
• Beck-Broichsitter M, Merkel OM, Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release. 2012;161:214–224.
   PubMed Web of Science ®Google Scholar
• El-Sherbiny IM, El-Baz NM, Yacoub MH. Inhaled nano- and microparticles for drug delivery. Glob Cardiol Sci Pract. 2015;2015:2.
   PubMedGoogle Scholar
• Carvalho TC, Peters JI, Williams RO. 3rd, Influence of particle size on regional lung deposition-what evidence is there? Int J Pharm. 2011;406:1–10.
   PubMed Web of Science ®Google Scholar
• Koziolek M, Grimm M, Schneider F, et al. Navigating the human gastrointestinal tract for oral drug delivery: uncharted waters and new frontiers. Adv Drug Deliv Rev. 2016;101:75–88.
   PubMed Web of Science ®Google Scholar
• Sankar V, Hearnden V, Hull K, et al. Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral Dis. 2011;17(Suppl. 1):73–84.
   PubMed Web of Science ®Google Scholar
• Prinderre P, Sauzet C, Fuxen C. Advances in gastro retentive drug-delivery systems. Expert Opin Drug Deliv. 2011;8:1189–1203.
   PubMed Web of Science ®Google Scholar
• Tanno FK, Sakuma S, Masaoka Y, et al. Site-specific drug delivery to the middle region of the small intestine by application of enteric coating with hypromellose acetate succinate (HPMCAS). J Pharm Sci. 2008;97:2665–2679.
   PubMed Web of Science ®Google Scholar
• Jain A, Gupta Y, Jain SK. Azo chemistry and its potential for colonic delivery. Crit Rev Ther Drug Carrier Syst. 2006;23:349–400.
   PubMed Web of Science ®Google Scholar
• Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv. 2004;11:129–148.
   PubMed Web of Science ®Google Scholar
• Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech. 2015;16:731–741.
   PubMed Web of Science ®Google Scholar
• Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet. 1984; 9:1–25.
   PubMed Web of Science ®Google Scholar
• Dixon LJ, Barnes M, Tang H, et al. Kupffer cells in the liver. Compr Physiol. 2013;3:785–797.
   PubMed Web of Science ®Google Scholar
• Kmiec Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:III–XIII. 1-151.
   PubMedGoogle Scholar
• Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release. 2012;161:188–197.
   PubMed Web of Science ®Google Scholar
• Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol. 2010;176:14–21.
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release. 2015;203:126–139.
   PubMed Web of Science ®Google Scholar
• Greupink R, Bakker HI, Reker-Smit C, et al. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol. 2005;43:884–892.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172.
   PubMed Web of Science ®Google Scholar
• Huang L, Xie J, Bi Q, et al. Highly selective targeting of hepatic stellate cells for liver fibrosis treatment using a d-enantiomeric peptide ligand of Fn14 identified by mirror-image mRNA display. Mol Pharm. 2017;14:1742–1753.
   PubMedGoogle Scholar
• Hagens WI, Mattos A, Greupink R, et al. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res. 2007;24:566–574.
   PubMed Web of Science ®Google Scholar
• Koning GA, Morselt HW, Gorter A, et al. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res. 2003;20:1249–1257.
   PubMed Web of Science ®Google Scholar
• Garg M, Jain NK. Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J Drug Target. 2006;14:1–11.
   PubMed Web of Science ®Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:727241.
   PubMedGoogle Scholar
• Dalen DP, De Leeuw AM, Brouwer A, et al. Rat liver endothelial cells have a greater capacity than kupffer cells to endocytose N-acetylglucosamine- and mannose-terminated glycoproteins. Hepatol. 1987;7:672–679.
   PubMed Web of Science ®Google Scholar
• Kamps J, Morselt H, Swart PJ, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA. 1997;94:11681–11685.
   PubMed Web of Science ®Google Scholar
• Franssen EF, Koiter J, Kuipers C, et al. Low-molecular-weight proteins as carriers for renal drug targeting, reparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. J Med Chem. 1992;35:1246–1259.
   PubMed Web of Science ®Google Scholar
• Zhou P, Sun X, Zhang Z. Kidney-targeted drug delivery systems. Acta Pharm Sin B. 2014;4:37–42.
   PubMedGoogle Scholar
• Dikran Sarko RG. Kidney-specific drug delivery: review of opportunities, achievements, and challenges. J Anal Pharm Res. 2016;2:00033.
   Google Scholar
• Yuan ZX, Li J, Zhu D, et al. Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting. J Drug Target. 2011;19:540–551.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Susaki H, Okuno S, et al. Specific renal delivery of sugar-modified low-molecular-weight peptides. J Pharmacol Exp Ther. 1999;288:888–897.
   PubMed Web of Science ®Google Scholar
• Shirota K, Kato Y, Suzuki K, et al. Characterization of novel kidney-specific delivery system using an alkylglucoside vector. J Pharmacol Exp Ther. 2001;299:459–467.
   PubMed Web of Science ®Google Scholar
• Wilk S, Mizoguchi H, Orlowski M. gamma-Glutamyl dopa: a kidney-specific dopamine precursor. J Pharmacol Exp Ther. 1978;206:227–232.
   PubMed Web of Science ®Google Scholar
• Wang J, Masehi-Lano JJ, Chung EJ. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci. 2017;5:1450–1459.
   PubMed Web of Science ®Google Scholar
• Tuffin G, Waelti E, Huwyler J, et al. Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol. 2005;16:3295–3305.
   PubMed Web of Science ®Google Scholar
• Kim J, Cao L, Shvartsman D, et al. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 2011;11:694–700.
   PubMed Web of Science ®Google Scholar
• Ebner DC, Bialek P, El-Kattan AF, et al. Strategies for skeletal muscle targeting in drug discovery. Curr Pharm Des. 2015;21:1327–1336.
   PubMed Web of Science ®Google Scholar
• Kona S, Specht D, Rahimi M, et al. Targeted biodegradable nanoparticles for drug delivery to smooth muscle cells. J Nanosci Nanotech. 2012;12:236–244.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhong L, Nahid MA, et al. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv. 2014;11:345–364.
   PubMed Web of Science ®Google Scholar
• Tardi P, Wan CP, Mayer L. Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes. J Drug Target. 2016;24:797–804.
   PubMed Web of Science ®Google Scholar
• Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet. 2003;42:1319–1330.
   PubMed Web of Science ®Google Scholar
• Bauss F, Esswein A, Reiff K, et al. Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats. Calcif Tissue Int. 1996;59:168–173.
   PubMed Web of Science ®Google Scholar
• Yewle JN, Puleo DA, Bachas LG. Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone. Bioconjugate Chem. 2011;22:2496–2506.
   PubMed Web of Science ®Google Scholar
• Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des. 2002;8:1929–1944.
   PubMed Web of Science ®Google Scholar
• Zhang G, Guo B, Wu H, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012;18:307–314.
   PubMed Web of Science ®Google Scholar
• Liang C, Guo B, Wu H, et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med. 2015; 21:288–294.
   PubMed Web of Science ®Google Scholar
• Liu J, Dang L, Li D, et al. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials. 2015;52:148–160.
   PubMed Web of Science ®Google Scholar
• Wang D, Miller SC, Shlyakhtenko LS, et al. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjugate Chem. 2007;18:1375–1378.
   PubMed Web of Science ®Google Scholar
• Li CJ, Cheng P, Liang MK, et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest. 2015;125:1509–1522.
   PubMed Web of Science ®Google Scholar
• Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004; 10:625–632.
   PubMed Web of Science ®Google Scholar
• Won YW, Adhikary PP, Lim KS, et al. Oligopeptide complex for targeted non-viral gene delivery to adipocytes. Nature Mater. 2014;13:1157–1164.
   PubMed Web of Science ®Google Scholar
• Daquinag AC, Zhang Y, Amaya-Manzanares F, et al. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell. 2011;9:74–86.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. Neurorx. 2005;2:3–14.
   PubMedGoogle Scholar
• Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437–449.
   PubMed Web of Science ®Google Scholar
• Garg T, Bhandari S, Rath G, et al. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J Drug Target. 2015;23:865–887.
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94:1187–1195.
   PubMed Web of Science ®Google Scholar
• Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J. 2008;10:166–177.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Zhang Y, Pardridge WM. Blood-brain barrier disruption following the internal carotid arterial perfusion of alkyl glycerols. J Drug Target. 2002;10:463–467.
   PubMed Web of Science ®Google Scholar
• Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 1994;659:62–66.
   PubMed Web of Science ®Google Scholar
• Rautio J, Laine K, Gynther M, et al. Prodrug approaches for CNS delivery. AAPS J. 2008;10:92–102.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu X, Gong T, et al. In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery. Acta Pharmacol Sin. 2012;33:279–288.
   PubMed Web of Science ®Google Scholar
• Sutera FM, De Caro V, Giannola LI. Small endogenous molecules as moiety to improve targeting of CNS drugs. Expert Opin Drug Deliv. 2017;14:93–107.
   PubMed Web of Science ®Google Scholar
• Beduneau A, Saulnier P, Hindre F, et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments. Biomaterials. 2007;28: 4978–4990.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Kang YS, Buciak JL, et al. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res. 1995;12:807–816.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012;503:269–292.
   PubMed Web of Science ®Google Scholar
• Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24: 1759–1771.
   PubMed Web of Science ®Google Scholar
• Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16:108–123.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307:58–62.
   PubMed Web of Science ®Google Scholar
• Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release. 2015;201:78–89.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771–782.
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48: 416–427.
   PubMed Web of Science ®Google Scholar
• Ivanenkov VV, Felici F, Menon AG. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim Biophys Acta. 1999;1448:463–472.
   PubMed Web of Science ®Google Scholar
• Shadidi M, Sioud M. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. .FASEB J. 2003;17:256–258.
   PubMedGoogle Scholar
• Wu P, Leinonen J, Koivunen E, et al. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem. 2000;267:6212–6220.
   PubMedGoogle Scholar
• Renschler MF, Bhatt RR, Dower WJ, et al. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci USA. 1994;91:3623–3627.
   PubMed Web of Science ®Google Scholar
• Dybwad A, Lambin P, Sioud M, et al. Probing the specificity of human myeloma proteins with a random peptide phage library. Scand J Immunol. 2003;57:583–590.
   PubMed Web of Science ®Google Scholar
• Lee SM, Lee EJ, Hong HY, et al. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res. 2007;5:11–19.
   PubMed Web of Science ®Google Scholar
• He X, Na MH, Kim JS, et al. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol Pharm. 2011;8:430–438.
   PubMedGoogle Scholar
• Zhao X, Hu J, Huang R, et al. Identification of one vasculature specific phage-displayed peptide in human colon cancer. J Exp Clin Cancer Res. 2007;26:509–514.
   PubMed Web of Science ®Google Scholar
• Liang S, Lin T, Ding J, et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med. 2006;84:764–773.
   PubMed Web of Science ®Google Scholar
• Hetian L, Ping A, Shumei S, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem. 2002;277:43137–43142.
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–380.
   PubMed Web of Science ®Google Scholar
• Oku N, Asai T, Watanabe K, et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene. 2002;21:2662–2669.
   PubMed Web of Science ®Google Scholar
• Helmlinger G, Sckell A, Dellian M, et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res. 2002;8:1284–1291.
   PubMed Web of Science ®Google Scholar
• Lee ES, Shin HJ, Na K, et al. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release. 2003;90:363–374.
   PubMed Web of Science ®Google Scholar
• Cheng R, Feng F, Meng F, et al. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release. 2011;152:2–12.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Kim TI, et al. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm. 2009;6:718–726.
   PubMedGoogle Scholar
• Cerritelli S, Velluto D, Hubbell JA. PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules. 2007;8:1966–1972.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003;63:4062–4066.
   PubMed Web of Science ®Google Scholar
• Basel MT, Shrestha TB, Troyer DL, et al. Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS Nano. 2011;5:2162–2175.
   PubMed Web of Science ®Google Scholar
• Mock JN, Costyn LJ, Wilding SL, et al. Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer. Integr Biol. 2013;5:172–182.
   Google Scholar
• Zhu L, Huo Z, Wang L, et al. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm. 2009;370:136–143.
   PubMed Web of Science ®Google Scholar
• Xie J, Liu G, Eden HS, et al. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res. 2011;44:883–892.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Chen X, et al. Conjugation of paclitaxel to iron oxide nanoparticles for tumor imaging and therapy. Nanoscale. 2012;4:2306–2310.
   PubMed Web of Science ®Google Scholar
• Schroeder A, Avnir Y, Weisman S, et al. Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir. 2007;23:4019–4025.
   PubMed Web of Science ®Google Scholar
• Wang CH, Huang YF, Yeh CK. Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging. Langmuir. 2011;27:6971–6976.
   PubMed Web of Science ®Google Scholar
• Warram JM, Sorace AG, Saini R, et al. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med. 2011;30: 921–931.
   PubMed Web of Science ®Google Scholar
• Yavlovich A, Smith B, Gupta K, et al. Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol Membr Biol. 2010;27:364–381.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8:343–375.
   PubMed Web of Science ®Google Scholar
• Varkouhi AK, Scholte M, Storm G, et al. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151:220–228.
   PubMed Web of Science ®Google Scholar
• Wente SR. Gatekeepers of the nucleus. Science. 2000;288:1374–1377.
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346–358.
   PubMed Web of Science ®Google Scholar
• Kalderon D, Roberts BL, Richardson WD, et al. A short amino acid sequence able to specify nuclear location. Cell. 1984;39:499–509.
   PubMed Web of Science ®Google Scholar
• Sarko D, Beijer B, Garcia Boy R, et al. The pharmacokinetics of cell-penetrating peptides. Mol Pharm. 2010;7: 2224–2231.
   PubMed Web of Science ®Google Scholar
• Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release. 2007;118:216–224.
   PubMed Web of Science ®Google Scholar
• Shi M, Ho K, Keating A, et al. Doxorubicin-conjugated immuno-nanoparticles for intracellular anticancer drug delivery. Adv Funct Mater. 2009;19:1689–1696.
   Web of Science ®Google Scholar
• Shen Y, Zhou Z, Sui M, et al. Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery. Nanomedicine (Lond). 2010;5:1205–1217.
   PubMed Web of Science ®Google Scholar
• Moseley GW, Leyton DL, Glover DJ, et al. Enhancement of protein transduction-mediated nuclear delivery by interaction with dynein/microtubules. J Biotechnol. 2010; 145:222–225.
   PubMed Web of Science ®Google Scholar
• Xiong L, Du X, Kleitz F, et al. Cancer-cell-specific nuclear-targeted drug delivery by dual-ligand-modified mesoporous silica nanoparticles. Small. 2015;11:5919–5926.
   PubMed Web of Science ®Google Scholar
• Smith RA, Porteous CM, Coulter CV, et al. Selective targeting of an antioxidant to mitochondria. Eur J Biochem. 1999;263:709–716.
   PubMedGoogle Scholar
• Weissig V, Lasch J, Erdos G, et al. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res. 1998;15:334–337.
   PubMed Web of Science ®Google Scholar
• Weissig V. DQAsomes as the prototype of mitochondria-targeted pharmaceutical nanocarriers: preparation, characterization, and use. Methods Mol Biol. 2015;1265:1–11.
   PubMedGoogle Scholar
• Tanaka M, Borgeld HJ, Zhang J, et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci. 2002;9:534–541.
   PubMed Web of Science ®Google Scholar
• Parkinson-Lawrence EJ, Shandala T, Prodoehl M, et al. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology (Bethesda). 2010;25:102–115.
   PubMed Web of Science ®Google Scholar
• Brown VI, Greene MI. Molecular and cellular mechanisms of receptor-mediated endocytosis. DNA Cell Biol. 1991; 10:399–409.
   PubMed Web of Science ®Google Scholar
• Sly WS, Vogler C. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood–brain barrier. Proc Natl Acad Sci USA. 2002;99:5760–5762.
   PubMed Web of Science ®Google Scholar
• Behnke J, Eskelinen EL, Saftig P, et al. Two dileucine motifs mediate late endosomal/lysosomal targeting of transmembrane protein 192 (TMEM192) and a C-terminal cysteine residue is responsible for disulfide bond formation in TMEM192 homodimers. Biochem J. 2011;434:219–231.
   PubMed Web of Science ®Google Scholar
• Goswami S, Wang W, Arakawa T, et al. Developments and challenges for mAb-based therapeutics. Antibodies. 2013;2:452.
   Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767–774.
   PubMed Web of Science ®Google Scholar
• Mina LA, Sledge GW. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol. 2011;8:325–332.
   PubMed Web of Science ®Google Scholar
• Alsaggar M, Yao Q, Cai H, et al. Differential growth and responsiveness to cancer therapy of tumor cells in different environments. Clin Exp Metastasis. 2016;33:115–124.
   PubMed Web of Science ®Google Scholar
• Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010;37:311–320.
   PubMed Web of Science ®Google Scholar